Comparison
Company
Score
Quality
Valuation
Financial
Technical
Why is PharmaCyte Biotech, Inc. ?
Unrated Stock - No Analysis Available
Quality key factors
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-3.05%
EBIT to Interest (avg)
-6.76
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.42
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
17.55%
ROCE (avg)
0
ROE (avg)
9.07%
Valuation Key Factors 
Factor
Value
P/E Ratio
0
Industry P/E
Price to Book Value
0.17
EV to EBIT
2.17
EV to EBITDA
2.17
EV to Capital Employed
-0.42
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
43.35%
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
No Trend
Mildly Bullish
Technical Movement
5What is working for the Company
ROCE(HY)
Highest at 67.08%
RAW MATERIAL COST(Y)
Fallen by 0% (YoY
PRE-TAX PROFIT(Q)
At USD -0.81 MM has Grown at 54.82%
NET PROFIT(Q)
At USD -0.81 MM has Grown at 54.82%
-1What is not working for the Company
DEBT-EQUITY RATIO
(HY)
Highest at -29.94 %
Here's what is working for PharmaCyte Biotech, Inc.
Pre-Tax Profit
At USD -0.81 MM has Grown at 54.82%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
At USD -0.81 MM has Grown at 54.82%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for PharmaCyte Biotech, Inc.
Debt-Equity Ratio
Highest at -29.94 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio






